VERAXA Biotech at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

VERAXA Biotech brings 2 presentations to PEGS Europe 2026 in Lisbon. Its program covers two dual-targeting designs built for tumour selectivity in solid tumours, a conditionally active T cell engager and an avidity-driven antibody-drug conjugate.

OrganizationPEGS Europe 2026 Attendance
VERAXA Biotech
Heidelberg, Germany
veraxa.com
Biotech
Develops antibody-drug conjugates and bispecific T cell engagers for cancer, with its lead program in acute myeloid leukemia.
Talk
Tue Nov 17
9:00am–9:30am
Talk
Wed Nov 18
7:00pm–7:30pm
An Avidity-Driven, Dual-Targeting ADC with Superior Tumour Selectivity for the Treatment of Solid Tumours
Engineering Next-Generation Conjugates

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from VERAXA Biotech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction